ASH News Daily - Tuesday, December 13, 2011 - (Page A-2)
Page A–2
®
ASH News Daily
2011 Editorial Board
Editor
Joseph Mikhael,
MD, MEd
Mayo Clinic Arizona
Authors
Michael R. Bishop, MD
Medical College
of Wisconsin
Amanda M. Brandow,
DO, MS
Medical College of
Wisconsin
David Garcia, MD
University of New
Mexico Cancer Center
Shari A. Ghanny, MD
McMaster University
Heather Landau, MD
Memorial
Sloan-Kettering
Cancer Center
Julie A. Panepinto,
MD, MSPH
Medical College of
Wisconsin
Barbara Pro, MD
Fox Chase Cancer
Center
PLATELETS
The Plausibility of Platelets in Immunity
By david GaRcia, Md,
and ShaRi Ghanny, Md
versity of platelets and expanding
on the notion that they are more
than just mediators of hemostasis.
During the Scientific Committee
session, “Platelets in Disease of Inflammation,”
we learned about the
role of platelets in the progression of
vascular and inflammatory diseases.
Starting today at 7:30 a.m. in Ballroom
20D, San Diego Convention
Center, we will again have the opportunity
to learn about the various
functions of platelets during the Special
Symposium on the Basic Science
of Hemostasis and Thrombosis.
Dr. John Semple, St. Michael’s
Hospital, Toronto, Canada, will
start the session by discussing the
immune nature of platelets. In April
of this year, Dr. Semple et al. published
a comprehensive review outlining
the production, structure, and
function of platelets, in addition to
detailing the properties of platelets
that make them an integral part of
the hosts’ defense system. From
synthesizing and secreting inflammatory
mediators, to expressing cell
A
TRAINING
Translational Research Training in Hematology
2012 TRTH Participants:
Michael A.
Rosenzweig, MD
City of Hope
The information contained in ASH News
Daily is provided solely for educational
purposes. A diversity of opinions exists in
the field of hematology, and the articles
in this publication are often intended to
inform readers about more than one point of
view. These articles are not comprehensive
and should not be used as a substitute
for traditional sources of hematology
information, traditional diagnostic and
treatment information, or the individual
judgment of health-care providers. The
views expressed in ASH News Daily do not
necessarily represent ASH’s views, and their
inclusion in this publication should not be
interpreted as an endorsement by ASH.
ASH is not responsible for any inaccurate
or inappropriate use of the information,
publications, products, or services discussed
or advertised within.
©2011 by the American Society of Hematology
All materials contained in this newspaper
are protected by copyright laws and may not
be used, reproduced, or otherwise exploited
in any manner without the express prior
permission of ASH News Daily.
Contributing authors have declared
any financial interest in a product or in
potentially competing products, regardless
of the dollar amount. Any such financial
interest is noted with the author byline.
sponsored by ASH and the European
Hematology Association (EHA),
provides 20 early-career scientists
from around the world a unique,
yearlong training and mentoring
experience focused on building
successful careers in hematologic
translational research.
The TRTH program begins with
E
an intensive weeklong course held
March 17 through 23 in Milan, Italy.
The faculty are international leaders
in hematology and translational
research who cover biostatistics
and biomarkers, genetics and molecular
biology, ethics, and phase I
clinical study design. Mornings are
dedicated to didactic and interactive
sessions that further trainees’
understanding of translational research
methodology and regulatory
requirements. Afternoons are
devoted to small group sessions
in which trainees meet with their
TRTH mentors, peers, and faculty
to refine their individual research
proposals. The curriculum is specifically
designed to illustrate the
ach year the Translational Research
Training in Hematology
(TRTH) program, jointly
variety of pathways to a successful
career in hematology research.
The two follow-up meetings
provide additional opportunities
for trainees to develop professional
interaction with peers and mentors
and refine their research proposals.
The first follow-up meeting
takes place during the EHA Annual
Congress in June. At this meeting
TRTH trainees and faculty will
continue to refine projects through
small group mentoring sessions.
The second and final follow-up
meeting is held in conjunction
with the ASH annual meeting in
December. During this meeting,
TRTH trainees present progress
reports of their research projects
and careers since the conclusion of
the spring course.
“I see the TRTH program as an
incredible opportunity to meet
leaders in the field of hematology,
hear how they think by asking
scientific questions, and have
them help you develop your own
research projects. You also have
the chance to learn from your
peers across the globe, establishing
friendships and collaborations
Jennifer Amengual
Mattias Carlsten
Goda Choi
Rita Coutinho
Kara Davis
Stefan Deneberg
Francine Garrett-Bakelman
Florian Heidel
Anna Kalota
Cyrus Khandanpour
Olivier Kosmider
Andrew Lane
Luca Mazzarella
Filippo Milano
Anjali Mishra
Narcis Popescu
Raajit Rampal
Nina Rolf
Jessica Hoell Spitzer
Huichun Zhan
that last well beyond the year. I
highly recommend TRTH to anyone
beginning their transition
to independent research,” 2011
TRTH Participant Dr. Rafael Bejar,
Dana-Farber Cancer Institute,
said.
n area of focus during this
year’s annual meeting has
been exploring the true di-
surface receptors involved in the
immune response, platelets possess
diverse functions that enable them
to participate in immunity. Accord-
Special Symposium on the
Basic Science of Hemostasis
and Thrombosis
7:30 a.m.
Ballroom 20D, SDCC
ing to Dr. Semple, “Platelets are
more than just hemostatic elements.
They have the ability to control
many immune mechanisms and are
able to act as circulating sentinels
for bacteria and viruses, which they
can quickly present to cells [in] the
innate immune system.”
Next, Dr. Robert Flaumenhaft,
Harvard Medical School, Boston,
will discuss his research on modulators
of platelet protease-activated receptor-1
(PAR1). Activation of PAR1
on the platelet surface initiates an intracellular
G-protein signalling cascade,
leading to a procoagulant state.
“It is a great pleasure to discuss our
recent results not only to describe
their promise as a novel strategy
for inhibition of protease-activated
receptor-1 (PAR1), but also as an
example to bring to the attention
of members of the hemostasis and
thrombosis community opportunities
in small molecule development
that can be leveraged for their own
projects,” Dr. Flaumenhaft said.
The symposium will end with
the second abstract from Sunday’s
Plenary Scientific session. Sou Nakamura,
from Kyoto University’s
Centre for iPS Cell Research and
Application (CiRA), will discuss
his group’s research in regenerative
medicine and the establishment of
immortalized megakaryocyte progenitor
cells derived from human
induced pluripotent stem cells.
Don’t miss today’s symposium,
chaired by Drs. Jing-Fei Dong,
Baylor College of Medicine, Houston,
TX, Wadie F. Bahou, State
University of New York, Stony
Brook, NY, and Anna Falanga,
Ospedali Riuniti di Bergamo,
Bergamo, Italy, as it is sure to be
a day filled with new discovery;
attendees will learn more about
newly described platelet functions
in addition to recent advances in
our understanding of the complex
process of fibrin generation and
pathologic thrombosis.
Drs. Garcia and Ghanny indicated
no relevant conflicts of interest.
ASH NEWS DAILY
Tuesday, December 13, 2011
Table of Contents for the Digital Edition of ASH News Daily - Tuesday, December 13, 2011
ASH News Daily - Tuesday, December 13, 2011
https://www.nxtbookmedia.com